Arbutus Biopharma
ABUS
ABUS
99 hedge funds and large institutions have $144M invested in Arbutus Biopharma in 2023 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 36 increasing their positions, 23 reducing their positions, and 16 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more ownership
Funds ownership: →
less capital invested
Capital invested by funds: $ → $
11% less funds holding
Funds holding: 111 → 99 (-12)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
69% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 16
Holders
99
Holding in Top 10
2
Calls
$1.75M
Puts
$1.09M
Top Buyers
| 1 | +$7.72M | |
| 2 | +$4.57M | |
| 3 | +$2.65M | |
| 4 |
CC
Centiva Capital
New York
|
+$2.18M |
| 5 |
BlackRock
New York
|
+$618K |
Top Sellers
| 1 | -$7.81M | |
| 2 | -$755K | |
| 3 | -$739K | |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$566K |
| 5 |
DekaBank Deutsche Girozentrale
Frankfurt,
Germany
|
-$331K |